Immix Biopharma (NASDAQ:IMMX) Rating Increased to Hold at Wall Street Zen

Wall Street Zen upgraded shares of Immix Biopharma (NASDAQ:IMMX) from a sell rating to a hold rating in a research report report published on Saturday morning.

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Immix Biopharma in a research report on Thursday, January 22nd. One analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Immix Biopharma currently has an average rating of “Hold” and an average price target of $8.00.

Immix Biopharma Stock Down 2.0%

Shares of IMMX stock opened at $5.83 on Friday. Immix Biopharma has a 12-month low of $1.34 and a 12-month high of $7.73. The firm has a fifty day moving average of $5.30 and a 200-day moving average of $3.61. The firm has a market capitalization of $308.76 million, a price-to-earnings ratio of -7.57 and a beta of 0.31.

Immix Biopharma (NASDAQ:IMMX) last issued its quarterly earnings data on Friday, November 7th. The company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.19) by ($0.05). Research analysts expect that Immix Biopharma will post -0.87 earnings per share for the current year.

Hedge Funds Weigh In On Immix Biopharma

Hedge funds have recently made changes to their positions in the business. United Capital Financial Advisors LLC bought a new stake in shares of Immix Biopharma in the third quarter worth $148,000. Susquehanna International Group LLP increased its stake in Immix Biopharma by 78.8% in the 3rd quarter. Susquehanna International Group LLP now owns 90,858 shares of the company’s stock valued at $190,000 after buying an additional 40,032 shares during the last quarter. Citadel Advisors LLC bought a new stake in Immix Biopharma during the 3rd quarter worth about $188,000. Imprint Wealth LLC bought a new stake in Immix Biopharma during the 3rd quarter worth about $141,000. Finally, Tocqueville Asset Management L.P. boosted its stake in shares of Immix Biopharma by 37.4% during the 3rd quarter. Tocqueville Asset Management L.P. now owns 40,250 shares of the company’s stock worth $84,000 after buying an additional 10,950 shares during the last quarter. 11.26% of the stock is owned by institutional investors.

Immix Biopharma Company Profile

Immix Biopharma (NASDAQ:IMMX) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immuno-oncology therapies that target myeloid checkpoints. The company’s approach centers on harnessing the innate immune system to promote anti-tumor activity, complementing established T-cell checkpoint inhibitors. By modulating key myeloid pathways, Immix Biopharma aims to overcome resistance mechanisms in solid tumors and broaden the scope of effective cancer immunotherapy.

The company’s lead candidate, IMX-110, is a first-in-class combination therapy designed to activate macrophages and dendritic cells within the tumor microenvironment.